Articles by tag: intellia-therapeutics

In vivo gene editing: CRISPR therapy for hereditary angioedema

Single-dose CRISPR therapy NTLA-2002 reduced hereditary angioedema attacks by 87% in phase III. Learn how this will change treatment and pave the way to a cure.

In vivo gene editing: phase 3 of HAE therapy successful

First ever successful phase 3 in vivo gene editing: lonvo-z therapy reduces HAE attacks by 87%. Learn about the breakthrough and discontinuation of prophylaxis.